Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

NCT06455072 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER_GOV

Sponsor class

Conditions

Cervical Cancer

Interventions

DRUG: Nituzumab
DRUG: Serplulimab

Sponsor

Fujian Cancer Hospital

Collaborators

[object Object]